Russian science is making significant strides in oncology and neurology, with a wave of innovations emerging from research institutes and universities across the country. From "smart" capsules that deliver laser therapy directly to tumours to jellyfish-derived implants that repair brain tissue, Russia is positioning itself as a serious player in biomedical innovation.
The Smart Capsule Revolution
The innovation addresses a fundamental problem in photodynamic therapy: delivering photosensitisers directly to tumour cells while sparing healthy tissue.
“One of the most promising developments comes from Saratov State University, where researchers — in collaboration with colleagues from Armenia's National Academy of Sciences—have engineered a "smart" capsule for targeted cancer therapy.”
EuroAsia.News
The capsule uses calcium carbonate and ceruloplasmin — a protein that transports copper ions in the body — to protect and deliver therapeutic agents. According to Olga Inozemtseva, senior researcher at Saratov's Biomedical Photoacoustics Laboratory, "ceruloplasmin protects the photosensitiser from degradation caused by temperature and the chemical environment of various tissues". Importantly, ceruloplasmin also participates in generating reactive oxygen species, enhancing the therapeutic effect.
The results are striking: experiments demonstrated 86.9% loading efficiency of the photosensitiser, with complete release occurring after 48 hours. This gradual release allows high drug concentrations precisely in the tumour area while minimising exposure to healthy tissues. The team plans to move to animal models soon, bringing this technology closer to clinical application.
Reprogramming Brain Cancer Cells
Perhaps the most revolutionary work comes from a consortium of Russian institutions tackling glioma — one of the most aggressive and treatment-resistant brain tumours. Scientists from the Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, the Burdenko National Medical Research Centre for Neurosurgery, and Lomonosov Moscow State University have developed multiple innovative approaches.
For diagnosis, they created a PET/CT method using a new radiopharmaceutical compound built on radioactive aptamer molecules. When administered intravenously, these molecules selectively accumulate in tumour tissue, dramatically improving detection accuracy.
For therapy, researchers developed aptamers linked to anti-cancer agents for targeted delivery. Perhaps most remarkably, they are testing a molecular cocktail called GQ comby that effectively reprogrammes cancer cells — transforming them into safe, non-dividing healthy brain cells. Professor Galina Pavlova confirmed the preparations have demonstrated efficacy and are now being prepared for preclinical trials. This approach could fundamentally change how we treat brain cancer, moving from killing cancer cells to converting them.
Jellyfish-Derived Brain Repair
In a development that sounds like science fiction, researchers at Don State Technical University (DSTU) have turned to the brown jellyfish (Rhizostoma pulmo) to treat traumatic brain injury. With approximately 600,000 people suffering cranial trauma in Russia annually, this innovation addresses a critical gap.
Scientists developed a method to extract high-quality collagen from these jellyfish — a material structurally harder and with lower bacterial content than animal-derived alternatives. They created a porous collagen matrix impregnated with sodium thiosulfate, which ensures the slow release of hydrogen sulfide (H₂S). This gas molecule, naturally synthesised in neural tissue, has significant protective effects. However, after brain injury, H₂S levels plummet, triggering pathological processes. The new hybrid treatment maintains damaged tissue structure through the collagen matrix while H₂S release preserves nerve cells.
Project leader Stanislav Rodkin noted they are also "turning the environmental problem of Azov Sea brown jellyfish overpopulation into a source of high-value modern biomedical materials". Marine collagen offers significant advantages over animal proteins, being purer with lower bacterial contamination—making it ideal for medical applications.
Glioma Vaccines on the Horizon
The Federal Medical-Biological Agency (FMBA) has announced the imminent release of two vaccines against glioblastoma — the most aggressive form of brain cancer. Gliopept, a peptide vaccine, is expected to receive approval in 2026, while Gliorna, an mRNA vaccine, should be ready by year-end. These vaccines train the immune system to recognise and destroy tumour cells, potentially transforming glioblastoma treatment and establishing Russia as a global leader in this field.
## Complementary Innovations
Beyond these headline-grabbing developments, Russian researchers are advancing multiple fronts. Sechenov University scientists, in collaboration with Chinese colleagues, tested a laser-based method to destroy even the most resistant cancer cells, achieving a 2-3 times reduction in tumour cell density. Tomsk Polytechnic University researchers synthesised a magnetoelectric nanocomposite hydrogel that combines magnetic stimulation with anti-inflammatory properties to restore brain function after injury, successfully tested in animal models. And Siberian scientists completed phase I clinical trials of an oncolytic virus based on a recombinant vaccinia strain, which demonstrated efficacy against breast cancer tumours with 50% of patients showing stabilisation at terminal stages, and plans underway for brain tumour trials.
A New Era for Russian Biomedicine
From "smart" capsules to cellular reprogramming, and from jellyfish collagen to personalised vaccines, Russian biomedical science is demonstrating remarkable breadth and depth. These innovations, many supported by the Russian Science Foundation and the Ministry of Science and Higher Education, position Russia as an increasingly important contributor to global efforts against cancer and neurological disease. While many developments remain in preclinical stages, the momentum is undeniable.
